Clinical trials for Bladder / Urinary Tract / Urethral cancer

128 currently recruiting clinical trials
Phase 1 / Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT04752722 #2024-512900-20-00
Phase 2
Non-invasive bladder cancer Urothelial carcinoma Localized None 1 Systemic Treatment-Naive Immunotherapy
4 recruiting sites
enGene, Inc.
Phase 1 / Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT04752722 #2024-512900-20-00
Phase 1
Non-invasive bladder cancer Urothelial carcinoma Localized 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
enGene, Inc.
Phase 1 / Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT05706129 #2023-504254-35-00
Urothelial carcinoma Locally Advanced Metastatic 1 2 3 or more Immunotherapy Chemotherapy Antibody Drug Conjugates (ADC)
Systemic Treatment-Naive
8 recruiting sites
Debiopharm International SA
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT06781983
Locally Advanced Metastatic Other mutation 1 2 3 or more
Systemic Treatment-Naive
2 recruiting sites
Innate Pharma
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT06533059 #2024-515391-12-00
Locally Advanced Metastatic AKT 1 2 3 or more
BRAF HRAS KRAS G12C KRAS non G12C NRAS KRAS G12D Systemic Treatment-Naive
4 recruiting sites
Alterome Therapeutics, Inc.
Phase 1 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT04777994
Dose d'expansion cohorte combinaison avec inhibiteur PD-1 tumeurs MSI-H
Locally Advanced Metastatic MSI/dMMR 1 2 3 or more Immunotherapy
Systemic Treatment-Naive
4 recruiting sites
Calico Life Sciences LLC
Phase 1 Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Head and neck cancer Cervical / Vulvar / Vaginal cancer #NCT05176483 #2023-510061-10-00
NSCLC (Non-Small Cell Lung Cancer) Clear cell carcinoma Papillary carcinoma Other Invasive bladder cancer Upper excretory tract cancer Urethral cancer Oral cavity Oropharynx Hypopharynx Larynx Non-squamous NSCLC Adenocarcinoma Hepatocellular carcinoma Urothelial carcinoma Squamous cell carcinoma Other Locally Advanced Metastatic Metastatic Castration-resistant None 1 2 3 or more CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
12 recruiting sites
Exélixis
Phase 1 Breast cancer Lung cancer Pancreas cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Cervical / Vulvar / Vaginal cancer #NCT04389632
Parties A et B (escalade de dose)
NSCLC (Non-Small Cell Lung Cancer) Stomach Oesogastric junction Esophagus Invasive bladder cancer Epithelial ovarian cancer Squamous NSCLC Non-squamous NSCLC Adenocarcinoma Squamous cell carcinoma Urothelial carcinoma Serous high grade carcinoma (HGSOC) Other HER2 Negative Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
3 recruiting sites
Seagen
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06220864 #2025-520557-36-00
Escalade et extension de dose monothérapie et escalade de dose combinaison
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Synnovation Therapeutics, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06253871
HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1 2 3 or more
Systemic Treatment-Naive
3 recruiting sites
Iambic Therapeutics, Inc